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OBJECTIVES: to estimate economic consequences and
patients acceptance of a program proposing a switch
toward self-injection of a recombinant Human erythro-
poïetin (r-HuEPO) NeoRecormon with Reco-Pen® in a
population of adult patients on dialysis. METHODS: A
cost-minimisation study was performed in a societal 
perspective to assess the economic consequences of the
program proposing Reco-Pen®, to facilitate self-injection
in patients requiring a treatment with r-HuEPO. A
random national sample of French patients in mainte-
nance dialysis or in pre-dialysis were selected. A nurse
was dedicated in each centre to educate and assist patients
during the study period. Direct costs of injecting r-
HuEPO before and after the program were estimated
including purchase of the device and erythropoïetin, time
spent by nurses for injection and education of patients or
caregivers. Data were collected on all relevant items ret-
rospectively and prospectively during a 2-month follow
up period. An acceptance study was conducted including
self-evaluation of pain during injection, easiness of use
and satisfaction. RESULTS: One hundred twenty-four
patients in 42 centres were enrolled in Fall 2001. Eighty-
seven percent of patients were in maintenance therapy
and the rest in correction phase. The satisfaction scores
were positive in 80% of patients in terms of improved
autonomy and comfort and 93% declared themselves
ready to go on using the pen. The self-injection rates grew
from 21% to 53%. The switch to Reco-Pen® of 100
patient x year was associated with an economic gain of
€22,449 broken down as following: €18,725 corre-
sponding to the beneﬁt on r-HuEPO purchase cost,
€3,500 corresponding to the costs avoided by reducing
the number of injections performed by ofﬁce-based
nurses, and €224 due to the reduction of total time spent
by nurses in the centres. CONCLUSIONS: The short-
term acceptance of self-injection with Reco-Pen® in a
program proposing the assistance of dedicated nurses is
high and associated with an overall economic beneﬁt.
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TIVES: Because the outcomes and cost of caring for
patients with ESRD are of major concern, we analyzed
claims data of patients receiving exclusively either
Calcium Acetate (CA) or Sevelamer HCl (SHCl).
METHODS: From the California Medicaid (Medi-Cal)
program we compared 1401 ESRD patients who were
prescribed CA and 192 who were prescribed SHCl during
a 2-year period. RESULTS: For this population, the
median daily dose and cost were 4447mg ($0.55) for CA
and 4030mg for SHCl ($2.88), a signiﬁcant difference by
multivariate regression analysis that controlled for patient
demographics, co-morbidities, hospital admissions, and
time on binder. Not unexpectedly, comorbid conditions
such as COPD, diabetes, heart disease, and hypertension
were signiﬁcantly associated with costs and number of
hospital admissions. However, in patients who had been
prescribed binder for at least 12 months, there was no
statistically signiﬁcant association between choice of
binder, cardiovascular and other co-morbidities, down-
stream medical resource utilization or costs. Moreover,
there was no difference between the binders with regard
to time to ﬁrst hospitalization as well as the number of
hospital admissions. For a hypothetical cohort of 1000
ESRD patients treated over a 2-year period, the use of CA
as a ﬁrst-line agent, switching to SHCl only patients who
become hypercalcemic, would save almost $1.4 million
with no change in patient morbidity. Savings would be
substantially greater if the same approach is followed for
the entire US dialysis population. CONCLUSION: The
choice of phosphate binder does not have a signiﬁcant
impact on the medical costs (except cost of phosphate
binder), or number of hospitalizations, or time to hospi-
talization during follow-up for patients with ESRD.
However, implementing a 2-stage strategy for phosphate
binders has the potential to signiﬁcantly reduce the 
cost of managing hyperphosphatemia in ESRD patients
without having any detrimental effects on this 
population.
URINARY & KIDNEY DISEASES/DISORDERS—
Quality of Life/Preference Based Outcomes
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COMPARING SENSITIVITY TO CHANGE
BETWEEN I-QOL AND SF-36 IN A POPULATION
WITH URINARY INCONTINENCE
Bushnell DM, Martin M
Health Research Associates, Inc (HRA), Seattle, WA, USA
OBJECTIVE: To report comparisons of the sensitivity 
to change between a condition-speciﬁc quality-of-life
measure (I-QOL, speciﬁc to urinary incontinence) and 
a generic health status measure (SF-36). METHODS:
Incontinent female patients completed the I-QOL and the
SF-36 measures at screening, pre-treatment, and four sub-
sequent follow-up visits during participation in a multi-
center, double-blind, placebo-controlled randomized trial
to assess the efﬁcacy of duloxetine in the treatment of
patients with stress and mixed incontinence. Sensitivity
analyses were conducted using baseline and week 6 data
(or last observation carried forward if participant was an
early dropout). Only responders to stress pad test (25%
decrease), incontinent episodes (25% decrease) and per-
ceived global impression (a little better) were evaluated.
I-QOL scores and SF-36 scores are both transformed onto
a 0 – 100-point scale. RESULTS: For individuals having
a decrease in pad weight of at least 25%, change scores
of the SF-36 ranged from 0 (General Health) to 4 points
(Bodily Pain, Physical Functioning, Role Emotional, and
290 Abstracts
Role Physical) compared to a 9-point increase in I-QOL
total score. Those with a 25% decrease in incontinent
episodes had improvements ranging from 0 (General
Health) to 5 points (Physical Functioning) compared to a
10-point improvement in the I-QOL score. Those that
self-reported “a little” improvement in their urinary con-
dition had improvements of 6 points on the I-QOL and
-1 to 2 in 7 of the 8 subscales of the SF-36. CONCLU-
SION: In a clinical trial, condition-speciﬁc measures 
can provide greater sensitivity and offer a clearer 
interpretation.
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DEVELOPMENT OF A QUESTIONNAIRE TO
ASSESS QUALITY OF CARE IN DUTCH
DIALYSIS CENTERS
Oppe M,Weijnen TJ, de Charro FT
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OBJECTIVES: Dialysis patients have a chronic renal
insufﬁciency. For these patients process characteristics of
their treatment are important. Therefore this study aimed
at the development and testing of a questionnaire to
assess the quality of care in Dutch dialysis centers from
the patients perspective: the Quality of Care in Dialysis
centers (QCD) questionnaire. METHODS: In a literature
study possible sets of dimensions were identiﬁed. Four
focus group sessions were organized, with 27 patients in
total. The results from the focus groups were transformed
into a 68-item test version of the QCD. This version was
discussed with four nephrologists and seven patients. A
‘visual analogue scale’ (VAS) was added to determine
overall satisfaction. The ﬁnal test version was sent to 300
patients in a postal setting. Factor analysis was applied
and item reductions were conducted. RESULTS: Statisti-
cal analyses was based on 140 out of the 162 returned
questionnaires. The results from the factor analysis con-
ﬁrmed the use of the set of dimensions with the dimen-
sions: doctors, nurses, other staff members, and facilities.
The test version of the QCD instrument, was found to be
both construct valid and content valid. The instrument is
reliable, with Cronbach’s alpha of a = 0.91, a = 0.86, a
= 0.85 and a = 0.83 for four factors. After item reduc-
tion 36 items and the VAS remained. Each dimension con-
sists of 8 speciﬁc items and one item about the overall
satisfaction with that dimension. The 36-item QCD is
also content valid, construct valid and reliable (a = 0.83
and a = 0.84 for two factors). CONCLUSIONS: The
QCD can be used in Dutch dialysis centers. Further
research will be conducted to establish preference weights
per dimension on the basis of the VAS scores. These pref-
erence weights can be applied in benchmark procedures
to assess the quality of care in a dialysis center.
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OBJECTIVES: Prevalence rates of 16% have been
reported for overactive bladder (OAB). Despite the high
prevalence of overactive bladder (OAB), it is both an
under-diagnosed and underreported condition; less than
one half of community-dwelling persons with urinary
incontinence consult physicians about the problem. Once
symptoms develop many individuals explore treatment
options through a variety of channels depending on
symptom severity, perceived risk and the perceived value
gained from taking appropriate action. The purpose of
this study was to develop a self-administered question-
naire to measure perceived value for patients presenting
with symptoms of OAB. Psychometric evaluation of 
this questionnaire for scale development included item
development, item reduction and item analysis to assess
reliability and validity. METHODS: A questionnaire con-
sisting of 18 items was used for the study. Prior to inclu-
sion items were evaluated for both content and face
validity to ensure that they adequately represented the
value domain. The sample consisted of 50 patients from
a large clinic having symptoms of OAB. To be included,
participants were either male or female and were not
taking medications to treat their symptoms. Females had
to be pre-menopausal with no controls implemented for
hormone replacement therapy. Data were obtained via
telephone using trained interviewers. RESULTS: The
Kaiser-Meyer-Olkin (KMO) Measure of Sampling 
Adequacy for the ﬁnal principal components analysis 
was 0.774. The Bartlett Test of Sphericity was signiﬁcant
(0.0001), indicating the appropriate use of exploratory
factor analysis. Item reduction was accomplished by
examining item to total correlations and factor loadings.
Oblique rotation was used to obtain a ﬁnal factor solu-
tion consisting of four items, which explained 60% of the
variance. Cronbach’s alpha was 0.78 for the value scale.
CONCLUSIONS: A scale to assess perceived value was
developed that after undergoing psychometric evaluation
satisﬁed the criteria for scale reliability and validity.
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DISEASE-SPECIFIC PATIENT-REPORTED
OUTCOME MEASURES IN URINARY
INCONTINENCE
Patel KK, Neary M, Hakim Z
Hoffmann-La Roche Inc, Nutley, NJ, USA
Urinary incontinence (UI) is a multi-faceted disease that
may signiﬁcantly impact patients’ daily lives and health-
related quality of life (HRQoL). Most recently, a number
of measures applying various approaches have been
